drugmaker
Sanofi-Aventis said on Tuesday its anti-obesity drug
Acomplia had been
Sanofi's Acomplia Wins Swiss
Approval. 03 April, 2007
approval of this would-be blockbuster by giving manufacturer
Sanofi-Aventis one ?approvable?
Sanofi-Aventis still hopes to launch its eagerly awaited
BioPortfolio News
Approval recommendation boosts
Sanofi weight-loss pill
Acomplia Sanofi failed to win the agency's
approval to make
Acomplia available
(PDF)
ACOMPLIA (rimonabant) RECOMMENDED FOR
APPROVAL. IN THE EUROPEAN UNION. Paris, France, April 28, 2006 –
Sanofi-aventis announced today that the Committee for Medicinal
Acomplia | Zimulti, which will be tabled at FDA's Endocrinologic and Metabolic Drugs advisory panel on June 13 for its
approval for sale in the U.S
(PDF)
November 10, 2006
Sanofi-aventis announced today that
Acomplia_ (rimonabant)
The
approval of
Acomplia_ (rimonabant) a first in class product
A report of latest news and reviews about diet drug rimonabant /
Acomplia.
approval had to have been a disappointment for the French drugmaker,
Sanofi gave
It is said that if four people, standing on the four corners of an intersection,
This is not because any one report is inaccurate.
PARIS (XFN-ASIA) French pharmaceutical group
Sanofi-Aventis SA said it has won
approval from the European Commission to begin selling its anti-obesity drug
Acomplia.
A report of latest news and reviews about diet drug rimonabant /
Acomplia.
that
Sanofi has failed in both Germany and France to get
approval for state
Sanofi's Acomplia Wins Swiss
Approval. Tue, 03 April 2007
drugmaker
Sanofi-Aventis said on Tuesday its anti-obesity drug
Acomplia had been
The Motley Fool Positive study results are a load off the company's mind.
hands of the courts, plus any
Acomplia approval subject to the whims of the FDA,
04/2006
Approval Recommendation Boosts
Sanofi Weight-loss Pill
Acomplia Credit Card required for Free Trial. Get articles from 3,000 newspapers, magazines and
Obesity drug
Acomplia wins Mexican
approval ,
Sanofi-Aventis SA, France's
the obesity treatment
Acomplia in Mexico, the first
approval of the product in
.cc/about/
sanofi-says-no
-new-weight-loss-trial-needed-for-acomplia-approval.html 1. Sanofi Says No New Weight-Loss Trial Needed for Acomplia Approval
News and project information on the Acomplia (Rimonabant) obesity treatment drug, developed by Sanofi-Aventis. following regulatory approval by the EMEA in
acomplia sanofi. Post Reply. Posted by: kitybo. 06/20/2007, 00:45:59 FDA Advisory Panel Says Keep It Off the U.S. Approval for you or an increase in
sanofi aventis acomplia The individuals taking Acomplia diet and EU Acomplia potential side effects to Get U.S. Approval for our genes, not be used to shift
FRANKFURT (Thomson Financial) Sanofi-Aventis sees a good chance its Acomplia weight-loss and diabetes treatment will receive approval by the US Food and Drug
A report of latest news and reviews about diet drug rimonabant / Acomplia. Sanofi Hints Acomplia Approval Also Sought for 'Metabolic Disorders'
PARIS, April 26 (Reuters) French drugmaker Sanofi-Aventis <SASY.PA> said on Thursday that its anti-obesity Acomplia drug had received approval from Brazil's health
Tuesday indicates Sanofi-Aventis' weight-loss drug candidate Acomplia can help put the odds of Acomplia getting full approval by the FDA's February deadline
PARIS (Reuters) Sanofi-Aventis's anti-obesity drug Acomplia is facing three generic competitors in India even before it has won full approval from some markets,
Sanofi announced that the first country in which Acomplia will be sold is the United Kingdom. EU's approval was not a blanket approval, nor did it
Sanofi-Aventis has said that its experimental weight-loss drug Acomplia, which maker, applied for approval to sell Acomplia in the United States and Europe.
PARIS (Reuters) Sanofi-Aventis's anti-obesity drug Acomplia is facing three generic competitors in India even before it has won full approval from some markets,
Acomplia Results Boost Sanofi. By Robert Steyer. TheStreet.com Staff Reporter in February granted conditional approval for Acomplia as a weight-management
Sanofi-Aventis faces new delay in U.S. approval of diet pill Acomplia Diet Pills. Sanofi planned to submit 18 new drug applications for approval this
Although Sanofi-Aventis failed to get its obesity pill rimonabant approved in said incorrectly that Sanofi hoped to win approval for diabetes treatment with
decision on the approval for sale in the U.S. of Acomplia, known generically as "event" reports from Sanofi-Aventis related to Acomplia, the report said,